127 related articles for article (PubMed ID: 35180471)
1. USP18 reduces paclitaxol sensitivity of triple-negative breast cancer via autophagy.
Ge X; Zhang D; Song S; Mi Y; Shen Y; Jiang Q; Liang Y; Wang J; Ye Q
Biochem Biophys Res Commun; 2022 Apr; 599():120-126. PubMed ID: 35180471
[TBL] [Abstract][Full Text] [Related]
2. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
Li Y; Wang S; Wei X; Zhang S; Song Z; Chen X; Zhang J
Cancer Sci; 2019 Feb; 110(2):561-567. PubMed ID: 30467925
[TBL] [Abstract][Full Text] [Related]
3. SANT, a novel Chinese herbal monomer combination, decreasing tumor growth and angiogenesis via modulating autophagy in heparanase overexpressed triple-negative breast cancer.
Li QW; Zhang GL; Hao CX; Ma YF; Sun X; Zhang Y; Cao KX; Li BX; Yang GW; Wang XM
J Ethnopharmacol; 2021 Feb; 266():113430. PubMed ID: 33011366
[TBL] [Abstract][Full Text] [Related]
4. 20(R)-Panaxatriol enhances METTL3-mediated m
Li Y; Luo B; Lin X; Bai D; Li L; Gao D; Li X; Zhong X; Wei Y; Yang L; Zhu X; Han L; Tian H; Zhang R; Wang P
Phytomedicine; 2024 Jul; 130():155537. PubMed ID: 38823344
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
[TBL] [Abstract][Full Text] [Related]
6. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
7. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
8. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
[TBL] [Abstract][Full Text] [Related]
10. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
Li L; Wang J; Feng L; Fan J; Wang J; Tan N; Wang Z
J Ethnopharmacol; 2021 Sep; 277():114184. PubMed ID: 33961996
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
13. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
[TBL] [Abstract][Full Text] [Related]
14. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
15. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract][Full Text] [Related]
16. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
17. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage.
Reeder A; Attar M; Nazario L; Bathula C; Zhang A; Hochbaum D; Roy E; Cooper KL; Oesterreich S; Davidson NE; Neumann CA; Flint MS
Br J Cancer; 2015 Apr; 112(9):1461-70. PubMed ID: 25880007
[TBL] [Abstract][Full Text] [Related]
18. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
[No Abstract] [Full Text] [Related]
19. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.
Das CK; Linder B; Bonn F; Rothweiler F; Dikic I; Michaelis M; Cinatl J; Mandal M; Kögel D
Neoplasia; 2018 Mar; 20(3):263-279. PubMed ID: 29462756
[TBL] [Abstract][Full Text] [Related]
20. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
